ANI Pharmaceuticals ANIP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $923.71M+4.6% | $883.37M+6.8% | $826.88M+10.6% | $747.4M+10.9% | $674.07M+9.7% | ||
| $361.86M+6.0% | $341.31M+6.2% | $321.32M+10.4% | $291.01M+6.2% | $274.09M+9.5% | ||
| $561.85M+3.7% | $542.06M+7.2% | $505.56M+10.8% | $456.39M+14.1% | $399.98M+9.8% | ||
| 60.8%-0.5pp | 61.4%+0.2pp | 61.1%+0.1pp | 61.1%+1.7pp | 59.3%+0.1pp | ||
| $51.7M+0.1% | $51.66M-7.8% | $56.05M+4.0% | $53.87M+20.7% | $44.63M+0.1% | ||
| $314.87M-0.9% | $317.75M+4.3% | $304.67M-0.8% | $307.09M+10.4% | $278.14M+11.4% | ||
| $799.92M+3.6% | $772.27M+2.3% | $754.93M+3.1% | $732.21M+9.7% | $667.6M+8.8% | ||
| $123.79M+11.4% | $111.09M— | —— | —— | —— | ||
| 13.4%+0.8pp | 12.6%— | —— | —— | —— | ||
| -$18.35M+8.5% | -$20.06M+7.4% | -$21.66M-12.4% | -$19.27M-4.2% | -$18.49M-5.0% | ||
| $1.09M-43.9% | $1.93M+758% | -$294K+85.1% | -$1.98M+48.0% | -$3.8M+5.7% | ||
| $116.03M+21.1% | $95.79M+89.5% | $50.55M+443% | -$14.75M+46.5% | -$27.56M-24.1% | ||
| $23.88M+36.8% | $17.45M+74.9% | $9.98M+320% | -$4.54M+30.3% | -$6.51M-76.5% | ||
| $92.15M+17.6% | $78.34M+93.1% | $40.57M+497% | -$10.21M+51.5% | -$21.05M-13.6% | ||
| 10%+1.1pp | 8.9%+4.0pp | 4.9%+6.3pp | -1.4%+1.8pp | -3.1%-0.1pp | ||
| $751K-35.1% | $1.16M-26.0% | $1.56M-3.8% | $1.63M0.0% | $1.63M0.0% | ||
| $3.94+17.6% | $3.35+106% | $1.63+312% | -$0.77+39.4% | -$1.27-11.4% | ||
| $4.11+17.4% | $3.50+105% | $1.71+328% | -$0.75+40.5% | -$1.26-12.5% | ||
| 84.2M+1.8% | 82.7M+2.4% | 80.8M+2.1% | 79.1M+1.3% | 78.1M+0.8% | ||
| 80.9M+1.6% | 79.6M+0.9% | 78.8M+0.9% | 78.2M+0.7% | 77.7M+0.7% | ||
| $9.5M+236% | $2.82M— | —— | —— | —— | ||
| -$18.35M+8.5% | -$20.06M+7.4% | -$21.66M-12.4% | -$19.27M-4.2% | -$18.49M-5.0% | ||
| -$19.1M+38.4% | -$31.01M-14.1% | -$27.18M-129% | -$11.88M+7.2% | -$12.8M-1,968% | ||
| $1.09M-43.9% | $1.93M+758% | -$294K+85.1% | -$1.98M+48.0% | -$3.8M+5.7% | ||
| $923.71M+4.6% | $883.37M+6.8% | $826.88M+10.6% | $747.4M+10.9% | $674.07M+9.7% | ||
| $123.79M+11.4% | $111.09M+96.5% | $56.55M+27,028% | -$210K+97.6% | -$8.93M+39.7% | ||
| $213.23M+5.3% | $202.51M+36.9% | $147.95M+75.5% | $84.31M+25.8% | $67M+26.6% | ||
| $213.23M+5.3% | $202.51M+36.9% | $147.95M+75.5% | $84.31M+25.8% | $67M+26.6% | ||
| 23.1%+0.2pp | 22.9%+5.0pp | 17.9%+6.6pp | 11.3%+1.3pp | 9.9%+1.3pp | ||
| $123.79M+11.4% | $111.09M+96.5% | $56.55M+27,028% | -$210K+97.6% | -$8.93M+39.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ANI Pharmaceuticals's revenue?
- ANI Pharmaceuticals (ANIP) generated $923.7M in revenue over the trailing twelve months, up 37.0% year over year.
- Is ANI Pharmaceuticals profitable?
- ANI Pharmaceuticals reported $92.1M in net income over the trailing twelve months, a 10.0% net margin.
- What are ANI Pharmaceuticals's profit margins?
- Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.
- What is ANI Pharmaceuticals's earnings per share?
- ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $3.94.
- Where does ANI Pharmaceuticals's income statement data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
